revealed that the company had paid £21.7m to health organisations and professionals in just three years as part of a campaign to boost its influence in the UK.
The action on Thursday followed a 2021 complaint from a “concerned” health professional that the company hadthrough its sponsorship of obesity medicine training events, which the complainant alleged included attempts to bribe participants to prescribe another of its weight-loss drugs, Saxenda. In the case of Novo Nordisk, the breaches were “very serious”, said Laura Squire, chief healthcare quality and access officer at the MHRA.
Nice said it was assessing evidence that suggests some of those who provided it with expert submissions did not follow its “robust policy” on declaring interests., we are reviewing the declarations of interests from organisations and experts who provided advice to our committee that undertook the appraisal of semaglutide [Wegovy],” it said.